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Induction chemotherapy with a novel triplet regimen before 
consolidation radiotherapy in unresectable stage III non-small cell 
lung cancer (NSCLC): final analysis of a phase II study.
Schallier, Denis C.; Neyns, Bart; Fontaine, Christel; Ilsen, Bart; 
Meysman, Marc; Bral, Samuel; Everaert, Hendrik; De Greve, Jacques 
UZ Brussel, Brussels, Belgium
Background: the current treatment of patients (pts) with unresectable 
stage III NSCLC with chemotherapy and radiotherapy administered 
either sequentially or concomitantly remains unsatisfactory. Treat-
ment efﬁcacy and long-term outcome may be enhanced by using more 
powerful drugs or drug regimens or methods to optimize radio and che-
motherapy delivery. In the present phase II study, the contribution of a 
novel triplet regimen preceding radiotherapy on efﬁcacy and long-term 
outcome in unresectable stage III NSCLC was assessed.
Methods: 3 cycles of paclitaxel (175mg/m2 by 3 hour infusion on day 
1), carboplatin (AUC 5mg/ml.min. by IV bolus on day 1) and gem-
citabine (1000mg/m2 by IV bolus on day 1 and 8) (PACCAGE) were 
administered every 3 weeks in pts with a Karnofsky Performance Score 
(PS) of ≥ 80 and normal baseline lab evaluation. Toxicity was assessed 
every week during cycle 1 and on day 1 and 8 in cycles 2 and 3. To 
assess response, CT-scan of the chest and 18FDG-PET was performed 
before and after 3 cycles of induction chemotherapy or earlier if indi-
cated. Radiotherapy (66 Gy in 33 sessions) started at least 4 weeks after 
the last chemotherapy administration.
Results: sixty-four pts (25 stage IIIA and 39 stage IIIB) received a total 
of 179 cycles. Eight pts did not receive the intended 3 cycles because 
of tumour (4) and treatment (4) related early events precluding further 
chemotherapy. In 47 pts full dose radiotherapy was administered, in 11 
a reduced dose and in 6 no radiotherapy was given. 
Haematological toxicity grade 3/4 during induction occurred most often 
on day 15 of cycles (% worst grade 3/4 toxicity during cycle 1: leuco-
penia 14/3; neutropenia: 27/25; thrombocytopenia: 13/6; anaemia: 2/2). 
Grade 3 non-hematological toxicity included anaphylaxis to paclitaxel 
(1) and gastro-enteritis during myeolosuppression (2). Using CT-scan 
for response evaluation 1 complete (CR) and 35 partial (PR) were ob-
served (ITT 55% c.i. 42.5 to 66.9%) (stage IIIA: 72% c.i. 44 to 89.6%; 
stage IIIB 44% c.i. 28 to 59%; p= 0.06). The median follow-up of 
surviving pts at time of evaluation was 28.1 month. The median time to 
progression (TTP) and survival (S) of all pts was 10.9 and 17.2.month 
respectively. The difference in median TTP and S between stage IIIA 
and IIIB pts (8.7.vs 15.0.month and 10.5 vs 23.3.month respectively) 
was statistically signiﬁcant for S only (p=0.096 and p=0.031). A meta-
bolic CR on 18FDG-PET was associated with a signiﬁcantly longer 
TTP and S compared to a non-CR (9.8 versus 19.9 month and 14.4 
versus 49 month, p=0.026 and p=0.004 respectively).
Conclusion: 3 cycles of induction chemotherapy with the novel PAC-
CAGE regimen in unresectable stage III NSCLC is active and well 
tolerated. Myelotoxicity on day 15 of the cycle constituted the main 
toxicity but was manageable. Whether the triplet is superior and offers 
a better cost-effectiveness compared to the currently used platinum-
doublets as induction chemotherapy should be evaluated in a ran-
domised study.
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A phase II study of induction CDDP+VNR+MMC followed by 
concomitant-boost thoracic radiotherapy with concurrent daily 
CDDP for unresectable locally advanced NSCLC (LA-NSCLC)
Shibata, Kazuhiko1 Kasahara, Kazuo2 Kita, Toshiyuki3 Shirasaki, 
Hiroki4 Takanaka, Tsuyoshi2 
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Background: While early concurrent chemoradiation is a mainstay of 
the treatment of LA-NSCLC, a new-drug combination is incapable of 
combining with radiotherapy concurrently in a full dose due to exces-
sive toxicity. Sequential chemoradiotherapy, or a full-dose induction 
new-generation chemotherapy followed by radiotherapy, should be 
explored. However, local control may be compromised due to a sequen-
tial use. Both concomitant-boost technique and concurrent daily CDDP 
have been reported to improve local effect of radiotherapy. The purpose 
of this trial is to examine the activity and safety of a induction full-dose 
new-generation triplet chemotherapy followed by locally-intensiﬁed 
radiotherapy using concomitant-boost technique and with concurrent 
daily CDDP.
Methods: This study was a multicentered phase II trial. The primary 
endpoint was response rate (RR), while secondary endpoints were 
toxicities, time to progression (TTP), pattern of relapse, and overall 
survival (OS). Eligibility criteria included previously untreated, inoper-
able stage III NSCLC; PS, 0-1; age ≤75 years; measurable lesion; 
adequate organ functions; absence of interstitial pneumonia; and writ-
ten informed consent. Two cycles of induction chemotherapy consisted 
of CDDP (80 mg/m2, day 1), VNR (25 mg/m2, days 1, 8), and MMC (8 
mg/m2, day 1) were administered every 3 weeks followed by thoracic 
radiotherapy using concomitant-boost technique with daily low-dose 
CDDP (6 mg/m2/d). Radiotherapy was delivered by 2 Gy/F over a large 
ﬁeld and 0.75 Gy/F over a smaller ﬁeld at the same day, ﬁve days a 
week, to a total dose of 60.5-66 Gy over 22-24 treatment days.
Results: A total of 36 pts were enrolled. Patient characteristics were: 
male/female 31/5;median age 63; stage IIIA/IIIB 11/25. Thirty four 
patients completed chemotherapy, and 32 completed the entire chemo-
radiotherapy. Major adverse events comprised of G4 neutropenia in 
27 pts (75%), and febrile neutropenia in 5 (13.8%), G3 esophagitis in 
4 (11.1%). There was no treatment-related death. Three pts achieved 
CR and 27 achieved PR with objective response rate of 83.3% (95% 
C.I., 67.2-93.6%). At October 1, 2006, median TTP and OS was 8.7 
M and 21.1 M, respectively. (median follow-up was 43 M). The actual 
2- and estimated 3-, 4-year survival rates were 47.2%, 44.1%, 39.2%, 
respectively.
Conclusions: These results indicate that this “delayed-hybrid” therapy 
is effective and well-tolerated. We concluded that this strategy is a 
candidate for comparison with early concurrent chemoradiotherapy in a 
phase III trial.
